About this Research Topic
The gastrointestinal (GI) tract is the habitat for a prosperous and miscellaneous community of microbes and is the highest colonized area of the body. The functional consequence of presence of the microbiota in GI tract is not yet fully understood, though a holistic and dynamic gut-microbiome interactions is critical for the regulation of GI physiology and many physiological processes of host, including metabolic and nutritional processes, maturation and regulation of the immune system. This further modulates the communication of gut with non-GI tissues. Moreover, gut-bacteria regulate the expression of several genes in intestinal epithelial cells (IECs) and regulate several metabolic pathways in the gut.
The interactions between gut and gut-microbiome are bidirectional. Therefore, pathological conditions alter these interactions due to changes in GI physiology or modifications in gut-microbiota community or both. This results in generation and translocation of gut derived danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) from GI lumen to the circulation and then to the non-GI tissues which amplify the pathogenesis and fasten the disease progression.
Many GI or non-GI related pathological conditions such as celiac disease, Crohn's disease, inflammatory bowel disease (IBD), diabetes, metabolic liver diseases (alcoholic and non-alcoholic steatohepatitis), biliary diseases (primary sclerosing cholangitis [PSC], primary biliary cholangitis [PBC], and biliary atresia [BA]) bring changes in GI physiology or gut-microbiota or both simultaneously. These generate various signaling mediators due shifts in gut-microbiome interactions. Some of these mediators such as LPS, certain metabolites and lipid molecules have already been found to be associated with the pathophysiology of several GI and non-GI related diseases. However, how these molecules generated in the gut, how gut-microbiota is associated with their generation is not well understood. Further, modulation of gut-microbiota interaction will limit the generation and translocation of gut derived DAMPs and PAMPs from GI lumen and help to abate the contribution of gut in disease pathogenesis is not well known. Thus, the major goal of this research topic is to understand the interactions of gut with gut-microbiota during physiological and GI/non-GI related pathological conditions.
This Research Topic aims to provide a forum for novel knowledge on the role of the gut-microbiota in the regulation of gut physiology via their functional interaction with gut, how these functional interactions between gut and gut-microbiota changes during pathological conditions, how these changes contribute to the GI and non-GI related pathological conditions as well as the potentials and downsides of gut microbiota-based therapies for these diseases. We welcome submissions of original Research and Review articles focusing on but not limited to the following aspects:
-Interactions between the gut and gut-microbiota under physiological conditions.
-Gut and gut-microbiota interaction in GI related diseases such as celiac disease, Crohn's disease, IBD etc.
-Gut and gut-microbiota interaction in non-GI related diseases such as diabetes, metabolic liver diseases etc.
- Gut and gut-microbiota interaction in Cholangiopathies such as BA, PSA, PBC.
The interactions between gut and gut-microbiome are bidirectional. Therefore, pathological conditions alter these interactions due to changes in GI physiology or modifications in gut-microbiota community or both. This results in generation and translocation of gut derived danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) from GI lumen to the circulation and then to the non-GI tissues which amplify the pathogenesis and fasten the disease progression.
Many GI or non-GI related pathological conditions such as celiac disease, Crohn's disease, inflammatory bowel disease (IBD), diabetes, metabolic liver diseases (alcoholic and non-alcoholic steatohepatitis), biliary diseases (primary sclerosing cholangitis [PSC], primary biliary cholangitis [PBC], and biliary atresia [BA]) bring changes in GI physiology or gut-microbiota or both simultaneously. These generate various signaling mediators due shifts in gut-microbiome interactions. Some of these mediators such as LPS, certain metabolites and lipid molecules have already been found to be associated with the pathophysiology of several GI and non-GI related diseases. However, how these molecules generated in the gut, how gut-microbiota is associated with their generation is not well understood. Further, modulation of gut-microbiota interaction will limit the generation and translocation of gut derived DAMPs and PAMPs from GI lumen and help to abate the contribution of gut in disease pathogenesis is not well known. Thus, the major goal of this research topic is to understand the interactions of gut with gut-microbiota during physiological and GI/non-GI related pathological conditions.
This Research Topic aims to provide a forum for novel knowledge on the role of the gut-microbiota in the regulation of gut physiology via their functional interaction with gut, how these functional interactions between gut and gut-microbiota changes during pathological conditions, how these changes contribute to the GI and non-GI related pathological conditions as well as the potentials and downsides of gut microbiota-based therapies for these diseases. We welcome submissions of original Research and Review articles focusing on but not limited to the following aspects:
-Interactions between the gut and gut-microbiota under physiological conditions.
-Gut and gut-microbiota interaction in GI related diseases such as celiac disease, Crohn's disease, IBD etc.
-Gut and gut-microbiota interaction in non-GI related diseases such as diabetes, metabolic liver diseases etc.
- Gut and gut-microbiota interaction in Cholangiopathies such as BA, PSA, PBC.
Keywords: gastrointestinal tract, microbiota, celiac disease, Crohn's disease, diabetes, metabolic liver diseases IBD
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
